Development of a novel ELISA to detect total factor D in the presence of high levels of PEGylated anti-factor D Fab
Abstract
Aim: PEGylated anti-Factor D Fab (PEG-aFD) was developed as a potential therapeutic for geographic atrophy, targeting factor D, the rate-limiting enzyme in the alternative complement pathway. An assay was needed to measure total factor D as a pharmacodynamic biomarker in human aqueous humor in the presence of high PEG-aFD concentrations. Results: Commercial kit met sensitivity requirement, but not drug tolerance requirement. In-house ELISA met both drug tolerance and sensitivity requirements. Addition of 100 ng/ml PEG-aFD to the sample diluent enabled accurate measurement of human factor D in the presence of 2.5 mg/ml of PEG-aFD in the in-house ELISA. Conclusion: Accurate measurement of total factor D in human aqueous humor containing high concentrations of PEG-aFD was achieved by adding PEG-aFD to sample diluent.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Prevalence of age-related macular degeneration in the US population. Arch. Ophthalmol. 129(1), 75–80 (2011).
- 2. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419–1431 (2006).
- 3. . Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J. Ophthalmol. 2012, 319728 (2012).
- 4. . Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements. Transl. Vis. Sci. Technol. 4(3), 6 (2015).
- 5. . Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes. Arch. Clin. Exp. Ophthalmol. 252(4), 647–655 (2014).
- 6. Writing Committee for the UKA-RMDEMRUG. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121(5), 1092–1101 (2014).
- 7. . The impact of PEGylation on biological therapies. BioDrugs 22(5), 315–329 (2008).
- 8. . Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology 121(5), 1079–1091 (2014).
- 9. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 53(10), 6628–6637 (2012). • The alternative complement pathway is activated in patients with age-related macular degeneration.
- 10. . Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest. Ophthalmol. Vis. Sci. 50(12), 5818–5827 (2009). • The alternative complement pathway is activated in patients with age-related macular degeneration.
- 11. Systemic complement activation in age-related macular degeneration. PLoS ONE 3(7), e2593 (2008). • The alternative complement pathway is activated in patients with age-related macular degeneration.
- 12. Population pharmacokinetics and pharmacodynamics of lampalizumab administered intravitreally to patients with geographic atrophy. CPT Pharmacometrics Syst. Pharmacol. 4(10), 595–604 (2015). •• Target-mediated drug disposition model of the pharmacokinetics and pharmacodynamics of lampalizumab and factor D.
